NCT05636657

Brief Summary

The disease activity index under intestinal color ultrasound was evaluated by SUS-CD, and the disease activity index under capsule endoscopy was evaluated by CECDAI. All subjects underwent intestinal color ultrasound and capsule endoscopy at baseline and at the third month of treatment. To compare the correlation between SUS-CD and CECDAI before and after treatment, and to compare the role of intestinal color ultrasound and capsule endoscopy in monitoring Crohn's disease in small intestine.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 2022

Completed
28 days until next milestone

Study Start

First participant enrolled

November 30, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 5, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2025

Completed
Last Updated

December 5, 2022

Status Verified

October 1, 2022

Enrollment Period

2.5 years

First QC Date

November 2, 2022

Last Update Submit

December 1, 2022

Conditions

Keywords

Intestinal Color UltrasoundCapsule EndoscopySUS-CDCECDAI

Outcome Measures

Primary Outcomes (4)

  • the Simple Ultrasound Activity Score for Crohn's Disease (SUS-CD)

    The Simple Ultrasound Score for Crohn's Disease \[SUS-CD\] is constituted by Bowel wall thickness (BWT) and colour Doppler. BWT:\<3 mm gets 0 score, 3 to 4.9 mm gets 1 score, 5 to 7.9 mm gets 2 scores, and intestinal wall thickness of ≥8 mm gets 3scores. Colour Doppler score:No or single vessel gets 0 score, 2-5 vessels per cm2 gets 1 score, \>5 vessels per cm2 gets 2 scores.

    At baseline

  • the Capsule Endoscopy Crohn's Disease Activity Index(CECDAI)

    The CECDAI was designed to evaluate three main parameters of Crohn's disease: inflammation (A), extent of disease (B), and stricture (C), in both the proximal and distal segments of the small bowel. The final score was calculated by adding the two segmental scores: CECDAI =(\[A1×B1\] +C1) +(\[A2×B2\] +C2).

    At baseline

  • the Simple Ultrasound Activity Score for Crohn's Disease (SUS-CD)

    The Simple Ultrasound Score for Crohn's Disease \[SUS-CD\] is constituted by Bowel wall thickness (BWT) and colour Doppler. BWT:\<3 mm gets 0 score, 3 to 4.9 mm gets 1 score, 5 to 7.9 mm gets 2 scores, and intestinal wall thickness of ≥8 mm gets 3scores. Colour Doppler score:No or single vessel gets 0 score, 2-5 vessels per cm2 gets 1 score, \>5 vessels per cm2 gets 2 scores.

    at the third month of treatment

  • the Capsule Endoscopy Crohn's Disease Activity Index(CECDAI)

    The CECDAI was designed to evaluate three main parameters of Crohn's disease: inflammation (A), extent of disease (B), and stricture (C), in both the proximal and distal segments of the small bowel. The final score was calculated by adding the two segmental scores: CECDAI =(\[A1×B1\] +C1) +(\[A2×B2\] +C2).

    at the third month of treatment

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with Crohn's disease according to the 2019 European Guidelines for Crohn's disease.

You may qualify if:

  • Patients diagnosed with Crohn's disease according to the 2019 European Guidelines for Crohn's disease;
  • Voluntarily sign an informed consent form.

You may not qualify if:

  • Patients with contraindications for capsule endoscopy;
  • In the judgment of the investigator, it is not suitable to participate in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NanFang Hospital of Southern Medical University

Guangzhou, Guangdong, 510515, China

Location

MeSH Terms

Conditions

Digestive System DiseasesInflammatory Bowel DiseasesCrohn Disease

Condition Hierarchy (Ancestors)

GastroenteritisGastrointestinal DiseasesIntestinal Diseases

Study Officials

  • Xinmei Zhao, doctor

    Nanfang Hospital, Southern Medical University

    STUDY CHAIR

Central Study Contacts

Xinmei Zhao, doctor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 2, 2022

First Posted

December 5, 2022

Study Start

November 30, 2022

Primary Completion

May 31, 2025

Study Completion

May 31, 2025

Last Updated

December 5, 2022

Record last verified: 2022-10

Locations